Registration: https://cirm.webex.com/cirm/onstage/g.php?d=809822305&t=a
MODERATOR
Ellen Feigal, M.D., Senior Vice President of Research and Development, CIRM
SPEAKERS
• John Hyde, M.D., Ph.D, Medical Officer, Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT), Office of Cellular, Tissue and Gene Therapies (OCTGT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
• Eduardo Marbán, M.D., Ph.D., Founder and Chairman of Scientific Advisory Board, Capricor, Inc. and Director, Cedars-Sinai Heart Institute, Mark S. Siegel Family Professor
• Jonathan D. Glass, M.D., Professor, Neurology and Pathology, Emory University School of Medicine
TOPICS
The focus of this webinar is on the Lessons Learned from IND/Phase I trials including overcoming the challenges, and addressing the regulatory issues, as stem cell based therapies move towards the clinic.
• Presentation by FDA – Considerations for Early Phase Clinical Trial Design in Cellular Therapies- issues the FDA considers in evaluating the risks vs. benefits of early phase trial proposals
• Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients
• Lessons learned from Phase I trial of autologous cardiosphere-derived stem cell product for myocardial infarction and comparison to new allogeneic trial with the same indication
• Questions and Answers
Advanced Registration is required! https://cirm.webex.com/cirm/onstage/g.php?d=809822305&t=a
To test your system setup, please go to: http://www.webex.com/lp/jointest/
The website will simulate joining a meeting and test if you are missing any software, etc.
If you have technical issues, please call Webex support at 866.229.3239.
